Remix Therapeutics Collaboration Agreement with Janssen Pharmaceutica NV

Gunderson Dettmer represented Remix Therapeutics, a Massachusetts-based biotech company, in its collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration will center on advancing small molecule therapeutics using the REMaster drug discovery platform to module RNA processing.

In the announcement of the agreement, co-founder and CEO of Remix Therapeutics Peter Smith Ph.D. said, “We look forward to collaborating with this innovative team. Janssen is an ideal strategic partner for our REMaster platform. This collaboration further validates the therapeutic potential of our proprietary REMaster drug discovery platform and provides additional resources to translate our cutting-edge science into new medicines.”

The Gunderson deal team was led by Tim Ehrlich and included Aliya Sanders and Alice Kuo.